Erasmus University Medical Center Rotterdam;Skylinedx B.V.
发明人:
Martinus Hendrikus Van Vliet,Pieter Sonneveld
申请号：
US15128082
公开号：
US20170101684A1
申请日:
2015.03.28
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The disclosure is in the field of medical treatments and relates to the treatment of cancer, in particular, multiple myeloma (MM). Even more in particular, it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular, subjects with a poor prognosis. In a particular embodiment, the disclosure provides a method of treatment wherein subjects with a poor prognosis are selected and treated with a proteasome inhibitor such as Bortezomib. The disclosure further provides means and methods for identifying subjects with a poor prognosis. More in particular, the disclosure provides a composition comprising a proteasome inhibitor for use in the treatment of a subject with multiple myeloma when the subject has been diagnosed with an amp1q chromosomal aberration.
